- Home
- XBIO
as 12-18-2024 12:45pm EST
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.
| Founded: | N/A | Country: | United States |
| Employees: | 4 | City: | FRAMINGHAM |
| Market Cap: | 6.3M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 22.9K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.65 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.78 - $5.20 | Next Earning Date: | 11-12-2024 |
| Revenue: | $2,523,427 | Revenue Growth: | 7.15% |
| Revenue Growth (this year): | -11.65% | Revenue Growth (next year): | -18.18% |
Latest Xenetic Biosciences Inc. News
XBIO Breaking Stock News: Dive into XBIO Ticker-Specific Updates for Smart Investing
ACCESSWIRE
a day ago
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
ACCESSWIRE
2 days ago
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
ACCESSWIRE
13 days ago
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
ACCESSWIRE
a month ago
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
ACCESSWIRE
a month ago
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Simply Wall St.
a month ago
Xenetic Biosciences Third Quarter 2024 Earnings: Misses Expectations
ACCESSWIRE
a month ago
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
Associated Press Finance
a month ago
Xenetic Biosciences: Q3 Earnings Snapshot
Compare XBIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XBIO Xenetic Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.